Page last updated: 2024-11-08

paromomycin sulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

paromomycin sulfate : An aminoglycoside sulfate salt resulting from the treatment of paromomycin with sulfuric acid. A broad-spectrum antibiotic, it is used for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID744636
SCHEMBL ID12862549
MeSH IDM0015971
PubMed CID441375
CHEMBL ID2206196
CHEBI ID7935
SCHEMBL ID3355
MeSH IDM0015971

Synonyms (111)

Synonym
HMS1672M04
5784-51-0
AKOS000661446
2-methyl-3-(2-methylpropyl)quinazolin-4(3h)-one
STK860062
391-03-7
AB00096642-01
SCHEMBL12862549
cambridge id 5784510
sr-01000438311
SR-01000438311-1
Z56799823
3-isobutyl-2-methylquinazolin-4(3h)-one
4(3h)-quinazolinone,2-methyl-3-(2-methylpropyl)-
2-methyl-3-isobutyl-4-quinazolone
2-methyl-3-(2-methylpropyl)-3,4-dihydroquinazolin-4-one
DTXSID50973412
3-isobutyl-2-methyl-4(3h)-quinazolinone
paromomycin sulfate
smr000058551
MLS000028384
1263-89-4
paromomycin sulphate (1:1)
humatin (tn)
paromomycin sulfate (jan/usp)
D00868
aminosidin sulfate
gabbroral
d-streptamine, o-2-amino-2-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1-3)-beta-d-ribofuranosyl-(1-5))-2-deoxy-, sulfate (salt)
aminosidine sulfate
einecs 215-031-7
humycin sulfate
aminosidine sulphate
paromomycin sulfate [jan]
o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1-3)-o-beta-d-ribofuranosyl-(1-5)-o-(2-amino-2-deoxy-alpha-d-glucopyranosyl-(1-4))-2-deoxystreptamine sulfate (salt)
gabbromicina
paromomycin sulphates
nsc-758421
paramicina
paricina
1600 antibiotic
tox21_112349
dtxcid0027806
dtxsid5047829 ,
paromomycin sulfate salt
7205-49-4
paromomycin, sulfate (1:1)
einecs 230-575-5
d-streptamine, o-2-amino-2-deoxy-alpha-d-glucopyranosyl-1-(1-4)-o-(o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1-3)-o-beta-d-ribofuranosyl-(1-5))-2-deoxy-, sulfate (1:1) (salt)
CHEBI:7935 ,
(1r,2r,3s,4r,6s)-4,6-diamino-2-{[3-o-(2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl)-beta-d-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-d-glucopyranoside sulfate
S4183
AKOS016009094
humagel
nsc 758421
d-streptamine, o-2-amino-2-deoxy-alpha-d-glucopyranosyl-(1.fwdarw.4)-o-(o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1.fwdarw.3)-beta-d-ribofuranosyl-(1.fwdarw.5))-2-deoxy-, sulfate (salt)
aminoxidin
paromomycin sulfate [usp:jan]
farmiglucin
sinosid
845nu6gjps ,
farminosidin
unii-845nu6gjps
estomycin sulfate
crestomycin sulfate
CHEMBL2206196
paromomycinsulfatesalt
AKOS015855755
SCHEMBL3355
paromomycine sulphate
KS-1378
CS-4433
LJRDOKAZOAKLDU-UDXJMMFXSA-N
Q-201537
paromomycin sulfate, antibiotic for culture media use only
paromomycin (sulfate)
HY-B0956
o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1->3)-o-beta-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-alpha-d-glucopyranosyl-(1->4))-2-deoxystreptamine sulfate (salt)
Z1551627167
(2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-(((2r,3s,4r,5s)-5-(((1r,2r,3s,5r,6s)-3,5-diamino-2-(((2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)
aminosidine sulfate;paromomycin sulfate salt
CCG-270398
Q27269495
fi-5853
paromomycini sulfas [who-ip latin]
d-streptamine, o-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-o-.beta.-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4))-2-deoxy-, sulfate (1:1)
paromomycin sulfate [who-ip]
paromomycin sulfate [usp monograph]
o-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-o-.beta.-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4))-2-deoxystreptamine sulfate (salt)
paromomycin sulfate [mart.]
d-streptamine, o-2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(o-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-.beta.-d-ribofuranosyl-(1->5))-2-deoxy-, sulphate (salt)
paromomycin sulfate [usp-rs]
paromomycin sulfate [vandf]
paromomycin sulfate [who-dd]
penicillamine [who-ip]
paromomycin sulfate [orange book]
d-streptamine, o-2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(o-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-.beta.-d-ribofuranosyl-(1->5))-2-deoxy-, sulfate (salt)
penicillaminum [who-ip latin]
o-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-o-.beta.-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4))-2-deoxystreptamine sulphate (salt)
paromomycin sulfate [mi]
DTXSID601335979
(2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-{[(2r,3s,4r,5s)-5-{[(1r,2r,3s,5r,6s)-3,5-diamino-2-{[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-hydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}oxane-3,4-diol; sulf
EN300-122766
(1r,2r,3s,4r,6s)-4,6-diamino-2-((3-o-(2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl)-beta-d-ribofuranosyl)oxy)-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-d-glucopyranoside sulfate
o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1->3)-o-beta-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-alpha-d-glucopyranosyl-(1->4))-2-deoxystreptamine sulphate (salt)
d-streptamine, o-2-amino-2-deoxy-alpha-d-glucopyranosyl-(1->4)-o-(o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1->3)-beta-d-ribofuranosyl-(1->5))-2-deoxy-, sulfate(salt)
d-streptamine, o-2-amino-2-deoxy-alpha-d-glucopyranosyl-(1->4)-o-(o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1->3)-beta-d-ribofuranosyl-(1->5))-2-deoxy-, sulfate (salt)
paromomycin sulfate (usp monograph)
d-streptamine, o-2-amino-2-deoxy-alpha-d-glucopyranosyl-(1->4)-o-(o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1->3)-beta-d-ribofuranosyl-(1->5))-2-deoxy-, sulphate (salt)
paromomycin sulfate (mart.)
paromomycin sulfate (usp-rs)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency26.60320.000229.305416,493.5996AID743079
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID717565Inhibition of ribosome-mediated protein synthesis in rabbit reticulocytes after 60 mins by coupled transcription/translation assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations.
AID276872Antibacterial activity against Bacillus subtilis ATCC 6633 at 80 ug/ml2006Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations.
AID717566Inhibition of ribosome S30 subunit-mediated protein synthesis in Escherichia coli after 60 mins by coupled transcription/translation assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations.
AID276863Antibacterial activity against Escherichia coli ATCC 25922 at 40 ug/ml2006Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations.
AID276870Effect on human PCDH15 R3X mutation translation level at 80 ug/ml2006Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations.
AID276869Suppression of human PCDH15 R3X mutation at 80 ug/ml2006Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID276871Antibacterial activity against Escherichia coli ATCC 25922 at 80 ug/ml2006Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations.
AID717554Antibacterial activity against Escherichia coli R477/100 by microdilution method2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations.
AID276862Effect on human PCDH15 R3X mutation translation level at 40 ug/ml2006Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations.
AID717551Inhibition of mitochondrial ribosome-mediated protein synthesis in human HeLa cells assessed as {35S]methionine incorporation by autoradiography2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID276861Suppression of human PCDH15 R3X mutation at 40 ug/ml2006Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations.
AID276864Antibacterial activity against Bacillus subtilis ATCC 6633 at 40 ug/ml2006Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID717549Selectivity ratio of IC50 for ribosome-mediated protein synthesis in rabbit reticulocytes to IC50 for ribosome S30 subunit-mediated protein synthesis in Escherichia coli2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations.
AID717555Cytotoxicity against human HEK293 cells assessed as cell viability after 48 hrs by XTT based calorimetric assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (13.33)29.6817
2010's11 (73.33)24.3611
2020's2 (13.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.04 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index107.81 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (67.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]